Trial Profile
Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms FOLFA
- 07 Jun 2022 Primary endpoint (Radiological progression-free survival according to the investigator) has been met, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results assessing ial safety and efficacy of aflibercept and infusional 5-fluorouracil/folinic acid combination versus LV5FU2 alone in older patients,presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 23 Mar 2022 Status changed from recruiting to completed.